A randomised trial to compare the effect of pre- or postoperative nandroparin on blood loss during elective caesarean section

Phlebology

Volumn 17, Issue 2, 2002, Pages 67-69

  Cornette, J ^a   Jacquemyn, Y ^a   Vercauteren, M ^b   Buytaert, P ^a  

^a Department of Obstetrics and Gynaecology ^*  (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Blood loss; Caesarean section; Deep vein thrombosis prophylaxis; Nandroparin

Indexed keywords

NADROPARIN;

ADULT; ARTICLE; BLEEDING; CESAREAN SECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG SAFETY; ELECTIVE SURGERY; FEMALE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; OUTCOMES RESEARCH; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURGICAL TECHNIQUE;

EID: 0036805562     PISSN: 02683555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005230200033     Document Type: Article

References (15)

1. Hirsh J. From unfractionated heparins to low molecular weight heparins. Acta Chir Scand Suppl 1990;556:42-50.
2. Leizorovicz A, Haugh M, Chapuis F-R, Samama M, Boissel J-P. Low molecular weight heparin in prevention of perioperative thrombosis. BMJ 1992;305:913-20.
3. Koppenhagen K, Adolf J, Matthes M, Tröster E, et al. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost 1992;67:627-30.
4. Fareed J, Walenga JM, Lassen M, Borris L, et al. Pharmacologic profile of a low molecular weight heparin (Enoxaparin): Experimental and clinical validation of the prophylactic antithrombotic effects. Acta Chir Scand Suppl 1990;556:75-90.
5. Fejgin M, Lourwood D. Low molecular weight heparins and their use in obstetrics and gynecology. Obstet Gynaecol Surv 1994;49:424-31.
6. du V Flory C. Sample size for beginners. BMJ 1993;306:1181-4.
7. Luegenbiehl DL. Improving visual estimation of blood volume on peripads. Am J Matern Child Nurs 1997;22:294-8.
8. Roberts WE. Emergent obstetric management of postpartum haemorrhage. Gynecol Clin North Am 1995;22:283-302.
9. Maillet P. Actualité sur les héparines de bas poids moleculaire. Phlebologie 1992;45:179-83.
10. Gibson J, Ekevall K, Walker I. Puerperal thromboprophylaxis: Comparison of the anti-Xa activity of enoxoparin and unfractionated heparin. Br J Obstet Gynaecol 1998;105:795-7.
11. Horlocker T, Heit J. Low molecular weight heparin: Biochemistry, pharmacology, perioperative prophylaxis regimens, and guidelines for regional anesthetic management. Anesth Analg 1997;85:874-85.
12. Bonnar J, Norris L, Greene R. Low molecular weight heparin for thromboprophylaxis during caesarean section. Thromb Res 1999;96:317-22.
13. Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: Study by direct fetal blood sampling under ultrasound. Thromb Res 1984;34:557-60.
14. Sturridge F, de Swiet M, Letsky E. The use of low molecular weight heparin for thromboprophylaxis in pregnancy. Br J Obstet Gynaecol 1994;101:69-71.
15. Nelson-Piercy C, Letsky E, de Swiet M,. Low molecular weight heparin for obstetric thromboprophylaxis: Experience of 69 pregnancies in 61 women at high risk. Am J Obstet Gynecol 1997;176:1062-8.